Regulatory Travere claims first FDA OK in rare kidney disease FSGS PharmaphorumShrugging off an earlier phase 3 disappointment, Travere's Filspari has become the first FDA-approved treatment for rare kidney disease FSGS.RegulatoryRare DiseaseRead full story pharminent April 14, 2026 (Last updated: April 14, 2026) Pharmaphorum Shrugging off an earlier phase 3 disappointment, Travere’s Filspari has become the first FDA-approved treatment for rare kidney disease FSGS. RegulatoryRare DiseaseRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Novo Nordisk and OpenAI forge alliance to drive speedy drug developmentNext: MSD, Daiichi Sankyo’s ifinatamab deruxtecan receives FDA priority Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
